126
Participants
Start Date
May 22, 2025
Primary Completion Date
December 31, 2028
Study Completion Date
December 31, 2028
KELIM
(i) Patients with KELIM =\>1 will receive radiological assessment and undergo internal debulking surgery if the disease is operable. (ii) Patients with KELIM \<1 will have alternative management, such as addition of bevacizumab or changing to dose-dense chemotherapy, and defer the interval debulking surgery
Carboplatin plus Paclitaxel
Neoadjuvant chemotherapy
Interval debulking surgery
Interval debulking surgery
NOT_YET_RECRUITING
Sun Yat-sen University Cancer Center, Guangzhou
NOT_YET_RECRUITING
The University of Hong Kong - Shenzhen Hospital, Shenzhen
NOT_YET_RECRUITING
Pamela Youde Nethersole Eastern HospitalPamela Y, Chai Wan
NOT_YET_RECRUITING
Queen Mary Hospital, Department of Clinical Oncology, Hong Kong
RECRUITING
The University of Hong Kong, Department of Obstetrics and Gynaecology, Hong Kong
NOT_YET_RECRUITING
United Christian Hospital, Kwun Tong
Queen Mary Hospital, Hong Kong
OTHER
United Christian Hospital
OTHER
Pamela Youde Nethersole Eastern Hospital
OTHER
The University of Hong Kong-Shenzhen Hospital
OTHER
Sun Yat-sen University Cancer Centre
UNKNOWN
The University of Hong Kong
OTHER